For several decades, renin‐angiotensin‐aldosterone system inhibitors (RAAS‐Is) (angiotensin‐converting enzyme inhibitors (ACE‐Is), angiotensin‐II type 1 receptor blockers (ARBs) and more recently direct renin inhibitors (DRIs)) have been employed to reduce the rate of progression of diabetes nephropathy in people with type 2 diabetes.19 The gene discussed is ACE; the disease is type 2 diabetes mellitus.